Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

<u>Listing of Claims:</u>

- 1. (previously presented) A condensation aerosol for delivery of diphenhydramine, wherein the condensation aerosol is formed by heating a thin layer containing diphenhydramine, on a solid support, to produce a vapor of diphenhydramine, and condensing the vapor to form a condensation aerosol characterized by less than 10% diphenhydramine degradation products by weight, and an MMAD of less than 5 microns.
- 2. (previously presented) The condensation aerosol according to Claim 1, wherein the diphenhydramine is a free base form of diphenhydramine.
- 3. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is formed at a rate greater than 10⁹ particles per second.
- 4. (previously presented) The condensation aerosol according to Claim 3, wherein the condensation aerosol is formed at a rate greater than 10^{10} particles per second.
 - 5. (cancelled)
- 6. (currently amended) A method of producing diphenhydramine in an aerosol form comprising:
- a. heating a thin layer containing diphenhydramine, on a solid support, to produce a vapor of the diphenhydramine, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

- 7. (original) The method according to Claim 6, wherein the diphenhydramine is a free base form of diphenhydramine.
- 8. (previously presented) The method according to Claim 6, wherein the condensation aerosol is formed at a rate greater than 10⁹ particles per second.
- 9. (previously presented) The method according to Claim 8, wherein the condensation aerosol is formed at a rate greater than 10¹⁰ particles per second.
- 10. (previously presented) A kit for delivering a diphenhydramine condensation aerosol comprising:
 - a. a thin layer containing diphenhydramine, on a solid support, and
- b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of diphenhydramine, and condensing the vapor to form a condensation aerosol characterized by less than 10% diphenhydramine degradation products by weight, and an MMAD of less than 5 microns.
- 11. (previously presented) The kit according to Claim 10, wherein the device comprises:
 - a. a flow through enclosure containing the solid support,
 - b. a power source that can be activated to heat the solid support, and
 - c. at least one portal through which air can be drawn by inhalation,

wherein activation of the power source is effective to produce a vapor of the drug, and drawing air through the enclosure is effective to condense the vapor to form the condensation aerosol.

- 12. (previously presented) The kit according to Claim 10, further including instructions for use.
- 13. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

- 14. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 15. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.
- 16. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.
- 17. (currently amended) The condensation aerosol according to Claim 15 16, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.
- 18. (previously presented) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.
- 19. (previously presented) The method according to Claim 6, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.
- 20. (previously presented) The method according to Claim 6, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 21. (previously presented) The method according to Claim 6, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.
- 22. (previously presented) The method according to Claim 6, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.
- 23. (previously presented) The method according to Claim 22, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

- 24. (previously presented) The method according to Claim 6, wherein the solid support is a metal foil.
- 25. (previously presented) The kit according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.
- 26. (previously presented) The kit according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 27. (previously presented) The kit according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.
- 28. (previously presented) The kit according to Claim 11, wherein the solid support has a surface to mass ratio of greater than 1 cm² per gram.
- 29. (previously presented) The kit according to Claim 11, wherein the solid support has a surface to volume ratio of greater than 100 per meter.
- 30. (previously presented) The kit according to Claim 11, wherein the solid support is a metal foil.
- 31. (previously presented) The kit according to Claim 30, wherein the metal foil has a thickness of less than 0.25 mm.